| 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on … Authors/Task Force Members, MF Piepoli, AW Hoes, S Agewall, C Albus, ... European journal of preventive cardiology 23 (11), NP1-NP96, 2016 | 6250 | 2016 |
| 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and … B Williams, G Mancia, W Spiering, E Agabiti Rosei, M Azizi, M Burnier, ... European heart journal 39 (33), 3021-3104, 2018 | 4902 | 2018 |
| Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies Emerging Risk Factors Collaboration The Lancet 375 (9733), 2215-2222, 2010 | 3626 | 2010 |
| ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular … Authors/Task Force Members, L Rydén, PJ Grant, SD Anker, C Berne, ... European heart journal 34 (39), 3035-3087, 2013 | 3187* | 2013 |
| Genetic studies of body mass index yield new insights for obesity biology AE Locke, B Kahali, SI Berndt, AE Justice, TH Pers, FR Day, C Powell, ... Nature 518 (7538), 197-206, 2015 | 2986 | 2015 |
| Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials N Sattar, D Preiss, HM Murray, P Welsh, BM Buckley, AJM de Craen, ... The Lancet 375 (9716), 735-742, 2010 | 2650 | 2010 |
| Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes Q Yang, TE Graham, N Mody, F Preitner, OD Peroni, JM Zabolotny, ... Nature 436 (7049), 356-362, 2005 | 2552 | 2005 |
| Major lipids, apolipoproteins, and risk of vascular disease R Assessment Jama 302 (18), 1993-2000, 2009 | 2327 | 2009 |
| Diabetes mellitus, fasting glucose, and risk of cause-specific death Emerging Risk Factors Collaboration New England Journal of Medicine 364 (9), 829-841, 2011 | 2119 | 2011 |
| Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study N Sattar, A Gaw, O Scherbakova, I Ford, DSJ O’Reilly, SM Haffner, C Isles, ... Circulation 108 (4), 414-419, 2003 | 1947 | 2003 |
| EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis MJL Peters, DPM Symmons, D McCarey, BAC Dijkmans, P Nicola, ... Annals of the rheumatic diseases 69 (2), 325-331, 2010 | 1839 | 2010 |
| Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials KK Ray, SRK Seshasai, S Wijesuriya, R Sivakumaran, S Nethercott, ... The Lancet 373 (9677), 1765-1772, 2009 | 1591 | 2009 |
| Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis D Preiss, SRK Seshasai, P Welsh, SA Murphy, JE Ho, DD Waters, ... Jama 305 (24), 2556-2564, 2011 | 1562 | 2011 |
| Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents E Di Angelantonio, SN Bhupathiraju, D Wormser, P Gao, S Kaptoge, ... The Lancet 388 (10046), 776-786, 2016 | 1293 | 2016 |
| Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis N Sattar, DW McCarey, H Capell, IB McInnes Circulation 108 (24), 2957-2963, 2003 | 1231 | 2003 |
| Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study DJ Freeman, J Norrie, N Sattar, RDG Neely, SM Cobbe, I Ford, C Isles, ... Circulation 103 (3), 357-362, 2001 | 1196 | 2001 |
| Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS) AM Wallace, AD McMahon, CJ Packard, A Kelly, J Shepherd, A Gaw, ... Circulation 104 (25), 3052-3056, 2001 | 1125 | 2001 |
| Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial DW McCarey, IB McInnes, R Madhok, R Hampson, O Scherbakova, I Ford, ... The Lancet 363 (9426), 2015-2021, 2004 | 1049 | 2004 |
| C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study DJ Freeman, J Norrie, MJ Caslake, A Gaw, I Ford, GDO Lowe, ... Diabetes 51 (5), 1596-1600, 2002 | 1034 | 2002 |
| C-reactive protein, fibrinogen, and cardiovascular disease prediction Emerging Risk Factors Collaboration New England Journal of Medicine 367 (14), 1310-1320, 2012 | 995 | 2012 |
David PreissAssociate Professor, University of OxfordVerified email at ndph.ox.ac.uk
